サマリー

糖尿病はグリコーゲン代謝異常症の主な疾患である。
市場の分析と洞察。グリコーゲン代謝異常症治療薬の世界市場
COVID-19の流行により、グリコーゲン代謝疾患用医薬品の世界市場規模は2022年に百万米ドル相当と推定され、レビュー期間中にCAGR %で2028年までに百万米ドルに再調整されると予測されています。この健康危機による経済変化を十分に考慮し、2021年にグリコーゲン代謝疾患治療薬の世界市場の％を占めるOTCは、2028年までに百万米ドルの価値を持ち、ポストCOVID-19期間に修正された％のCAGRで成長すると予測されます。一方、病院セグメントは、この予測期間を通して％CAGRに変更されています。

中国のグリコーゲン代謝疾患治療薬の市場規模は2021年に百万米ドル、米国と欧州のグリコーゲン代謝疾患治療薬はそれぞれ百万米ドル、百万米ドルとされています。米国の割合は2021年に％、中国と欧州はそれぞれ％、％であり、中国の割合は2028年に％に達すると予測され、分析期間を通じてCAGRは％であると追跡しています。日本、韓国、東南アジアはアジアで注目すべき市場であり、今後6年間のCAGRはそれぞれ％、％、％となっています。欧州のグリコーゲン代謝疾患治療薬の展望としては、ドイツが2028年までに100万米ドルに達すると予測され、予測期間中のCAGRは%となっています。
グリコーゲン代謝疾患治療薬の世界的な主要メーカーは、Merck、Novartis、武田薬品、Astra Zeneca、Boehringer Ingelheim、KOWA、Kythera、富士薬品、LG Life Scienceなどであります。2021年、世界の上位5社は売上高で約 %のシェアを占めています。
世界のグリコーゲン代謝異常症治療薬の範囲とセグメント
グリコーゲン代謝異常症治療薬市場は、タイプ別と用途別に分類されます。グリコーゲン代謝疾患治療薬の世界市場におけるプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができるようになることでしょう。セグメント別分析では、2017年から2028年までのタイプ別およびアプリケーション別の売上、収益、予測に焦点を当てています。

タイプ別セグメント
一般用医薬品
Rx医薬品
用途別セグメント
病院
小売店

会社別
メルク
ノバルティス
武田薬品工業
アストラゼネカ
ベーリンガーインゲルハイム
興和
カイテラ
富士薬品
LGライフサイエンス
田辺三菱製薬

地域別
北米
米国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋地域
中国
日本
韓国
インド
オーストラリア
中国 台湾
インドネシア
タイ
マレーシア
中南米
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
UAE

ページTOPに戻る

目次

1 Study Coverage
1.1 Drugs for Glycogen Metabolism Disease Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Glycogen Metabolism Disease Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 OTC
1.2.3 Rx Drugs
1.3 Market by Application
1.3.1 Global Drugs for Glycogen Metabolism Disease Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Drugs for Glycogen Metabolism Disease Sales Estimates and Forecasts 2017-2028
2.2 Global Drugs for Glycogen Metabolism Disease Revenue Estimates and Forecasts 2017-2028
2.3 Global Drugs for Glycogen Metabolism Disease Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Drugs for Glycogen Metabolism Disease Sales by Region
2.4.1 Global Drugs for Glycogen Metabolism Disease Sales by Region (2017-2022)
2.4.2 Global Sales Drugs for Glycogen Metabolism Disease by Region (2023-2028)
2.5 Global Drugs for Glycogen Metabolism Disease Revenue by Region
2.5.1 Global Drugs for Glycogen Metabolism Disease Revenue by Region (2017-2022)
2.5.2 Global Drugs for Glycogen Metabolism Disease Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Drugs for Glycogen Metabolism Disease Sales by Manufacturers
3.1.1 Global Top Drugs for Glycogen Metabolism Disease Manufacturers by Sales (2017-2022)
3.1.2 Global Drugs for Glycogen Metabolism Disease Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Drugs for Glycogen Metabolism Disease in 2021
3.2 Global Drugs for Glycogen Metabolism Disease Revenue by Manufacturers
3.2.1 Global Drugs for Glycogen Metabolism Disease Revenue by Manufacturers (2017-2022)
3.2.2 Global Drugs for Glycogen Metabolism Disease Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Drugs for Glycogen Metabolism Disease Revenue in 2021
3.3 Global Drugs for Glycogen Metabolism Disease Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Drugs for Glycogen Metabolism Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Drugs for Glycogen Metabolism Disease Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Drugs for Glycogen Metabolism Disease Sales by Type
4.1.1 Global Drugs for Glycogen Metabolism Disease Historical Sales by Type (2017-2022)
4.1.2 Global Drugs for Glycogen Metabolism Disease Forecasted Sales by Type (2023-2028)
4.1.3 Global Drugs for Glycogen Metabolism Disease Sales Market Share by Type (2017-2028)
4.2 Global Drugs for Glycogen Metabolism Disease Revenue by Type
4.2.1 Global Drugs for Glycogen Metabolism Disease Historical Revenue by Type (2017-2022)
4.2.2 Global Drugs for Glycogen Metabolism Disease Forecasted Revenue by Type (2023-2028)
4.2.3 Global Drugs for Glycogen Metabolism Disease Revenue Market Share by Type (2017-2028)
4.3 Global Drugs for Glycogen Metabolism Disease Price by Type
4.3.1 Global Drugs for Glycogen Metabolism Disease Price by Type (2017-2022)
4.3.2 Global Drugs for Glycogen Metabolism Disease Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Drugs for Glycogen Metabolism Disease Sales by Application
5.1.1 Global Drugs for Glycogen Metabolism Disease Historical Sales by Application (2017-2022)
5.1.2 Global Drugs for Glycogen Metabolism Disease Forecasted Sales by Application (2023-2028)
5.1.3 Global Drugs for Glycogen Metabolism Disease Sales Market Share by Application (2017-2028)
5.2 Global Drugs for Glycogen Metabolism Disease Revenue by Application
5.2.1 Global Drugs for Glycogen Metabolism Disease Historical Revenue by Application (2017-2022)
5.2.2 Global Drugs for Glycogen Metabolism Disease Forecasted Revenue by Application (2023-2028)
5.2.3 Global Drugs for Glycogen Metabolism Disease Revenue Market Share by Application (2017-2028)
5.3 Global Drugs for Glycogen Metabolism Disease Price by Application
5.3.1 Global Drugs for Glycogen Metabolism Disease Price by Application (2017-2022)
5.3.2 Global Drugs for Glycogen Metabolism Disease Price Forecast by Application (2023-2028)
6 North America
6.1 North America Drugs for Glycogen Metabolism Disease Market Size by Type
6.1.1 North America Drugs for Glycogen Metabolism Disease Sales by Type (2017-2028)
6.1.2 North America Drugs for Glycogen Metabolism Disease Revenue by Type (2017-2028)
6.2 North America Drugs for Glycogen Metabolism Disease Market Size by Application
6.2.1 North America Drugs for Glycogen Metabolism Disease Sales by Application (2017-2028)
6.2.2 North America Drugs for Glycogen Metabolism Disease Revenue by Application (2017-2028)
6.3 North America Drugs for Glycogen Metabolism Disease Market Size by Country
6.3.1 North America Drugs for Glycogen Metabolism Disease Sales by Country (2017-2028)
6.3.2 North America Drugs for Glycogen Metabolism Disease Revenue by Country (2017-2028)
6.3.3 the United States
6.3.4 Canada
7 Europe
7.1 Europe Drugs for Glycogen Metabolism Disease Market Size by Type
7.1.1 Europe Drugs for Glycogen Metabolism Disease Sales by Type (2017-2028)
7.1.2 Europe Drugs for Glycogen Metabolism Disease Revenue by Type (2017-2028)
7.2 Europe Drugs for Glycogen Metabolism Disease Market Size by Application
7.2.1 Europe Drugs for Glycogen Metabolism Disease Sales by Application (2017-2028)
7.2.2 Europe Drugs for Glycogen Metabolism Disease Revenue by Application (2017-2028)
7.3 Europe Drugs for Glycogen Metabolism Disease Market Size by Country
7.3.1 Europe Drugs for Glycogen Metabolism Disease Sales by Country (2017-2028)
7.3.2 Europe Drugs for Glycogen Metabolism Disease Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 UK
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Drugs for Glycogen Metabolism Disease Market Size by Type
8.1.1 Asia Pacific Drugs for Glycogen Metabolism Disease Sales by Type (2017-2028)
8.1.2 Asia Pacific Drugs for Glycogen Metabolism Disease Revenue by Type (2017-2028)
8.2 Asia Pacific Drugs for Glycogen Metabolism Disease Market Size by Application
8.2.1 Asia Pacific Drugs for Glycogen Metabolism Disease Sales by Application (2017-2028)
8.2.2 Asia Pacific Drugs for Glycogen Metabolism Disease Revenue by Application (2017-2028)
8.3 Asia Pacific Drugs for Glycogen Metabolism Disease Market Size by Region
8.3.1 Asia Pacific Drugs for Glycogen Metabolism Disease Sales by Region (2017-2028)
8.3.2 Asia Pacific Drugs for Glycogen Metabolism Disease Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Drugs for Glycogen Metabolism Disease Market Size by Type
9.1.1 Latin America Drugs for Glycogen Metabolism Disease Sales by Type (2017-2028)
9.1.2 Latin America Drugs for Glycogen Metabolism Disease Revenue by Type (2017-2028)
9.2 Latin America Drugs for Glycogen Metabolism Disease Market Size by Application
9.2.1 Latin America Drugs for Glycogen Metabolism Disease Sales by Application (2017-2028)
9.2.2 Latin America Drugs for Glycogen Metabolism Disease Revenue by Application (2017-2028)
9.3 Latin America Drugs for Glycogen Metabolism Disease Market Size by Country
9.3.1 Latin America Drugs for Glycogen Metabolism Disease Sales by Country (2017-2028)
9.3.2 Latin America Drugs for Glycogen Metabolism Disease Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Drugs for Glycogen Metabolism Disease Market Size by Type
10.1.1 Middle East and Africa Drugs for Glycogen Metabolism Disease Sales by Type (2017-2028)
10.1.2 Middle East and Africa Drugs for Glycogen Metabolism Disease Revenue by Type (2017-2028)
10.2 Middle East and Africa Drugs for Glycogen Metabolism Disease Market Size by Application
10.2.1 Middle East and Africa Drugs for Glycogen Metabolism Disease Sales by Application (2017-2028)
10.2.2 Middle East and Africa Drugs for Glycogen Metabolism Disease Revenue by Application (2017-2028)
10.3 Middle East and Africa Drugs for Glycogen Metabolism Disease Market Size by Country
10.3.1 Middle East and Africa Drugs for Glycogen Metabolism Disease Sales by Country (2017-2028)
10.3.2 Middle East and Africa Drugs for Glycogen Metabolism Disease Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Overview
11.1.3 Merck Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Merck Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Merck Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Overview
11.2.3 Novartis Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Novartis Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Novartis Recent Developments
11.3 Takeda Pharmaceutical
11.3.1 Takeda Pharmaceutical Corporation Information
11.3.2 Takeda Pharmaceutical Overview
11.3.3 Takeda Pharmaceutical Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Takeda Pharmaceutical Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Takeda Pharmaceutical Recent Developments
11.4 Astra Zeneca
11.4.1 Astra Zeneca Corporation Information
11.4.2 Astra Zeneca Overview
11.4.3 Astra Zeneca Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Astra Zeneca Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Astra Zeneca Recent Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Corporation Information
11.5.2 Boehringer Ingelheim Overview
11.5.3 Boehringer Ingelheim Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Boehringer Ingelheim Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Boehringer Ingelheim Recent Developments
11.6 KOWA
11.6.1 KOWA Corporation Information
11.6.2 KOWA Overview
11.6.3 KOWA Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 KOWA Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 KOWA Recent Developments
11.7 Kythera
11.7.1 Kythera Corporation Information
11.7.2 Kythera Overview
11.7.3 Kythera Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Kythera Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Kythera Recent Developments
11.8 Fuji yakuhin
11.8.1 Fuji yakuhin Corporation Information
11.8.2 Fuji yakuhin Overview
11.8.3 Fuji yakuhin Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Fuji yakuhin Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Fuji yakuhin Recent Developments
11.9 LG Life Science
11.9.1 LG Life Science Corporation Information
11.9.2 LG Life Science Overview
11.9.3 LG Life Science Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 LG Life Science Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 LG Life Science Recent Developments
11.10 Metsubishi Tanabe Pharma
11.10.1 Metsubishi Tanabe Pharma Corporation Information
11.10.2 Metsubishi Tanabe Pharma Overview
11.10.3 Metsubishi Tanabe Pharma Drugs for Glycogen Metabolism Disease Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Metsubishi Tanabe Pharma Drugs for Glycogen Metabolism Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Metsubishi Tanabe Pharma Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Drugs for Glycogen Metabolism Disease Industry Chain Analysis
12.2 Drugs for Glycogen Metabolism Disease Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Drugs for Glycogen Metabolism Disease Production Mode & Process
12.4 Drugs for Glycogen Metabolism Disease Sales and Marketing
12.4.1 Drugs for Glycogen Metabolism Disease Sales Channels
12.4.2 Drugs for Glycogen Metabolism Disease Distributors
12.5 Drugs for Glycogen Metabolism Disease Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Drugs for Glycogen Metabolism Disease Industry Trends
13.2 Drugs for Glycogen Metabolism Disease Market Drivers
13.3 Drugs for Glycogen Metabolism Disease Market Challenges
13.4 Drugs for Glycogen Metabolism Disease Market Restraints
14 Key Findings in The Global Drugs for Glycogen Metabolism Disease Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer